Jennifer Swainson
Biographic Data
| ID | 7590235 |
|---|---|
| NAME | Jennifer Swainson |
| GIVEN NAMES | Jennifer |
| FAMILY NAME | Swainson |
| SIGNATURE | SWAINSON J |
| AFFILIATIONS | University of Alberta |
| ORCID | 0000-0002-6071-1395 |
| VERIFIED | Yes |
| TOTAL WORKS | 3 |
| TOTAL CITATIONS | 0 |
| AUTHOR COUNT | 3 |
| EDITOR COUNT | 0 |
| FIRST PUBLICATION YEAR | 2022 |
| LATEST PUBLICATION YEAR | 2024 |
| H-INDEX | 0 |
Use of ketamine for treatment resistant depression
Evidence for the use of ketamine in resistant depression has grown in recent years, with evolving data to support and direct its clinical use. There is an increasing body of evidence to guide judicious use of ketamine in various clinical circumstances, for a population of patients with a high burden of suffering and morbidity. While large-scale, randomized controlled trials, comparative studies, and longer-term treatment outcomes is lacking, this…
A survey of drug liking and cravings in patients using sublingual or intranasal ketamine for treatment resistant depression
Ketamine has gained rapid popularity as a treatment option for treatment resistant depression (TRD). Though seen only in limited contexts, ketamine is a potential drug of abuse, addiction and diversion. Clinical ketamine studies to date have not systematically evaluated factors relevant to addiction risk in patients with TRD, but in treating patients with ketamine, risks of potential harms related to addiction must be considered. As clinical acce…
Intravenous ketamine for depression
Ketamine is a versatile medication with an emerging role for the treatment of numerous psychiatric conditions, including treatment resistant depression. Current psychiatry guidelines for its intravenous administration to treat depression recommend regular blood pressure monitoring and an aggressive approach to potential transient hypertensive episodes induced by ketamine infusions. While this approach is aimed at ensuring patient safety, it shoul…
No prominent works on this page.
A survey of drug liking and cravings in patients using sublingual or intranasal ketamine for treatment resistant depression
Ketamine has gained rapid popularity as a treatment option for treatment resistant depression (TRD). Though seen only in limited contexts, ketamine is a potential drug of abuse, addiction and diversion. Clinical ketamine studies to date have not systematically evaluated factors relevant to addiction risk in patients with TRD, but in treating patients with ketamine, risks of potential harms related to addiction must be considered. As clinical acce…
Intravenous ketamine for depression
Ketamine is a versatile medication with an emerging role for the treatment of numerous psychiatric conditions, including treatment resistant depression. Current psychiatry guidelines for its intravenous administration to treat depression recommend regular blood pressure monitoring and an aggressive approach to potential transient hypertensive episodes induced by ketamine infusions. While this approach is aimed at ensuring patient safety, it shoul…
Use of ketamine for treatment resistant depression
Evidence for the use of ketamine in resistant depression has grown in recent years, with evolving data to support and direct its clinical use. There is an increasing body of evidence to guide judicious use of ketamine in various clinical circumstances, for a population of patients with a high burden of suffering and morbidity. While large-scale, randomized controlled trials, comparative studies, and longer-term treatment outcomes is lacking, this…
Depression (economics (3 works) · Ketamine (3 works) · Medicine (3 works) · Psychiatry (3 works) · Treatment of Major Depression (3 works) · Tryptophan and brain disorders (3 works) · Intensive care medicine (2 works) · Addiction (1 works) · Adverse effect (1 works) · Alcoholism and Thiamine Deficiency (1 works)